{"ticker": {"uuid": "dd89e5ff-e054-4f68-8700-367fec5c9f35", "symbol": "CYCN", "name": "Cyclerion Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cyclerion Therapeutics (CYCN) Edges Lower, Testing Key Support Amid Low Volume - New Highs New Lows", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQQXhIemZkQWtZdmF1bDBZb2podWNjWk4ySjBieFBmcGF5LWU0Y0h6NXp1emRVTDc2Tkw4aHRGazU5QzluMGhvd2NHMFRDaHNMU0I1VVE1R1Fvc0pLc0JCUVBMdWlWeVd0bm1nYUNDLVI4MjhUV3hrdmRfeDgyZUpLRjBaZDJsa0hwQS1UVTRNc09tWTNRbTRlbEVxWnlfSkZKcE1BNV9fSnJSWEl1ZXJycTU5TlRMajhJcHdr?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-15T00:30:26+00:00", "published_display": "15 Jul 2026 00:30", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal", "summary": "Cyclerion Therapeutics plans a reverse merger with privately held Korsana Biosciences, combined with a concurrent $380 million private placement. The new entity will focus on neurodegenerative diseases, particularly Alzheimer's, utilizing Korsana's THETA blood-brain barrier platf", "url": "https://www.stocktitan.net/sec-filings/CYCN/425-cyclerion-therapeutics-inc-business-combination-communication-65f7e735e4c8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:10:50", "published_display": "10 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDGAR Filing Documents for 0001193125-26-301054", "summary": "This SEC filing details a Form 425 submission by Cyclerion Therapeutics, Inc., accessible via the EDGAR system. The filing, with accession number 0001193125-26-301054, was made on July 10, 2026, and includes numerous documents and graphic files related to prospectuses and communi", "url": "https://www.sec.gov/Archives/edgar/data/1755237/000119312526301054/0001193125-26-301054-index.htm", "source_name": "SEC.gov", "published_at": "2026-07-10T15:39:35", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQUmRTd1BWdlNOSVVTRlRIOGZXUXRLS25HdXdiRFB1aHdkV2xBTHVkbjhZem52TmNBdXd1RmVKUGQwWTdrUEdFNGFaOEFuMWN4enREaU5HRFI0bVJyTko1bGVjSGtoQ0J6RUdIcDRKcS1DNUZ4dHZ6QXNrR2dNWkF4b0hKRDBiaDdBX2VRV2pSYi1NMWRyQlR2RFc0a0xHbWJjRnBSTHM4eU1fREhVeTZ1MkZzRkk3UFByUUJlSXZOZHNIWUkxX1BOS2Fhdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T10:05:52+00:00", "published_display": "10 Jul 2026 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. \u2013 NASDAQ:CYCN", "summary": "The article focuses on the enterprise value to forward revenue metric for Cyclerion Therapeutics, Inc. (NASDAQ: CYCN). It presents this financial data point for the company. The content appears to be a financial data snippet from TradingView, part of a larger analysis tool.", "url": "https://www.tradingview.com/symbols/NASDAQ-CYCN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:35", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cyclerion Therapeutics, Inc. \u2013 NASDAQ:CYCN", "summary": "This article provides a brief snapshot of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) focusing on its forward price to sales metric. It highlights the company's financial data availability on TradingView, indicating no current trades and a closed market status. The content is prim", "url": "https://www.tradingview.com/symbols/NASDAQ-CYCN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:43", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN)", "summary": "This article provides an overview of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) including its stock performance, market capitalization, and financial estimates. It highlights key financial data such as net income and EBITDA, and answers frequently asked questions regarding the c", "url": "https://www.tradingview.com/symbols/NASDAQ-CYCN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:41:29", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key Resistance - Triple MA Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOUVCRTRobng5R09DcDRfU0ttMlViQlNuZVItanRHajRndDg2RmI2cHhIbU9WRXphaDdfY1RCbDBzMU4zRThLNS1fT0tUb3J6dUpPSkhLMi1oWTB4WEs4SURvUTlPNTZYVE5OVWEzY3MtTVM2Yk10MnBCUE00MUV2TU8wWjJEUUtYT0NWOWhTZnhrcVRKb1E3UnJSN1lQMTBnQmUzbG1feW96OWVSVHZ6d1luOUdUVEtJcUpJ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey.com discusses Cyclerion Therapeutics Inc (CYCN) and its revenue breakdown. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides basic stock inf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cycn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:16", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis", "summary": "Cyclerion Therapeutics Inc (CYCN) currently holds a valuation score of 8.51, positioning it 126th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -2.44, indicating a significant deviation from its recent high and low P/E va", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cycn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T04:40:48", "published_display": "16 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Company Profile & Introduction", "summary": "This document provides a company profile and introduction for Cyclerion Therapeutics. Further details about the company's operations, financial health, or strategic initiatives would be found within the full content of such a profile.", "url": "https://www.moomoo.com/stock/CYCN-US/company?chain_id=Name1K9-3FXPhg.1ksr1qg&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A62,%22f%22%3A%22mm%2Fcommunity%2Fnnq%22%7D", "source_name": "Moomoo", "published_at": "2026-05-28T00:10:04", "published_display": "28 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[10-Q] Cyclerion Therapeutics, Inc. Quarterly Earnings Report", "summary": "Cyclerion Therapeutics reported a wider net loss of $3.2 million in Q1 2026 with no revenue, while operating expenses rose. The company faces a significant cash crunch, with funds expected to last only into Q3 2026, prompting substantial doubt about its ability to continue as a g", "url": "https://www.stocktitan.net/sec-filings/CYCN/10-q-cyclerion-therapeutics-inc-quarterly-earnings-report-3de9078065ab.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:39:45", "published_display": "12 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G", "summary": "FMR LLC has reported a 15.0% beneficial ownership stake in Cyclerion Therapeutics (NASDAQ: CYCN), as detailed in a Schedule 13G filing. The investment firm beneficially owns 649,547 shares of common stock as of April 30, 2026, with sole dispositive power. This includes holdings b", "url": "https://www.stocktitan.net/sec-filings/CYCN/schedule-13g-cyclerion-therapeutics-inc-passive-investment-disclosure-747ebc5daaa8.html", "source_name": "Stock Titan", "published_at": "2026-05-07T14:39:35", "published_display": "07 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating Organon & Co. (OGN), TruBridge, Inc. (TBRG), and Cyclerion Therapeutics, Inc. (CYCN) for potential violations of federal securities laws and breaches of fiduciary duties related to their recent or proposed transactio", "url": "https://www.sahmcapital.com/news/content/are-ogn-tbrg-cycn-obtaining-fair-deals-for-their-shareholders-2026-05-04", "source_name": "Sahm", "published_at": "2026-05-04T22:39:30", "published_display": "04 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading", "summary": "This page provides an overview of insider trading activity for Cyclerion Therapeutics, Inc. (CYCN), alongside other financial data. It indicates no recent insider trading by directors and management, and no congressional trading data for the ticker. The article also lists signifi", "url": "https://www.quiverquant.com/stock/CYCN/insiders/", "source_name": "Quiver Quantitative", "published_at": "2026-05-03T06:11:00", "published_display": "03 May 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details", "summary": "Cyclerion Therapeutics filed an amended annual report (10-K/A) to provide detailed disclosures on its board structure, executive compensation, and share ownership, which were previously omitted. The report highlights an independent chairman, three key board committees, and polici", "url": "https://www.stocktitan.net/sec-filings/CYCN/10-k-a-cyclerion-therapeutics-inc-amends-annual-report-d02ab0a422dc.html", "source_name": "Stock Titan", "published_at": "2026-04-30T12:39:14", "published_display": "30 Apr 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN SEC Filings - Cyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for investors and traders to access Cyclerion Therapeutics (CYCN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details how these documents offer insights into the company's", "url": "https://www.stocktitan.net/sec-filings/CYCN/page-2.html", "source_name": "Stock Titan", "published_at": "2026-04-29T08:40:21", "published_display": "29 Apr 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy", "summary": "Cyclerion Therapeutics and Korsana Biosciences have merged to form a new entity, Korsana Biosciences (KRSA), focused on developing neurodegenerative disease treatments. The combined company will prioritize KRSA-028, a new antibody targeting amyloid beta for Alzheimer's disease, u", "url": "https://www.harianbasis.co/en/cyclerion-korsana-merger-alzheimer-research", "source_name": "HarianBasis.co", "published_at": "2026-04-22T12:09:51", "published_display": "22 Apr 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer\u2019s Pipeline", "summary": "Cyclerion Therapeutics (NASDAQ:CYCN) has merged with Korsana Biosciences to form a new entity, also named Korsana Biosciences, trading under the ticker 'KRSA'. The merger aims to advance Korsana's neurodegenerative pipeline, specifically targeting Alzheimer's disease with KRSA-02", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cyclerion-therapeutics-cycn-merges-korsana-141501551.html", "source_name": "Market source", "published_at": "2026-04-20T16:15:00", "published_display": "20 Apr 2026 16:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korsana deal gives investors control; Cyclerion to become Korsana Biosciences (CYCN \u2192 KRSA)", "summary": "Cyclerion Therapeutics is merging with Korsana Biosciences, a privately held biotechnology company focused on neurodegenerative diseases. The merger will result in current Korsana shareholders owning approximately 98.5% of the combined company, which will be renamed Korsana Biosc", "url": "https://www.stocktitan.net/sec-filings/CYCN/s-4-cyclerion-therapeutics-inc-business-combination-registration-47f61d19e9a1.html", "source_name": "Stock Titan", "published_at": "2026-04-17T16:40:20", "published_display": "17 Apr 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing", "summary": "Cyclerion Therapeutics (CYCN) went up 350% in after-hours trading following the announcement of its merger with Korsana, a private biotechnology firm. The combined entity, specializing in therapies for inflammatory, fibrotic, and renal diseases, will be capitalized with $380 mill", "url": "https://www.msn.com/en-us/health/other/cyclerion-therapeutics-stock-soars-350-on-korsana-merger-380-million-financing/ar-AA1ZVt5m", "source_name": "MSN", "published_at": "2026-04-14T15:09:48", "published_display": "14 Apr 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time", "summary": "Replimune is implementing job cuts after the FDA rejected its drug candidate, RP1, for a second time. This development is part of a broader \"Finance Watch\" update which also covers Cyclerion, Kezar, and IO Biotech exploring strategic alternatives. The recurring FDA rejection for ", "url": "https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-replimune-cutting-jobs-as-fda-rejects-rp1-a-second-time-R7NN6KDVMVB65EL2YQQVSNVLJA/", "source_name": "Citeline News & Insights", "published_at": "2026-04-10T22:39:00", "published_display": "10 Apr 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating UniFirst (UNF), National Storage Affiliates Trust (NSA), Cyclerion Therapeutics (CYCN), and Urgent.ly (ULYX) for potential violations of federal securities laws and breaches of fiduciary duties related to their propo", "url": "https://www.prnewswire.com/news-releases/are-unf-nsa-cycn-ulyx-obtaining-fair-deals-for-their-shareholders-302738661.html", "source_name": "PR Newswire", "published_at": "2026-04-09T19:09:15", "published_display": "09 Apr 2026 19:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s company Korsana heads to NASDAQ via merger: Deals Report", "summary": "Korsana Biosciences Inc., an Alzheimer's focused company, will go public on NASDAQ through a reverse merger with Cyclerion Therapeutics Inc. (NASDAQ:CYCN). Korsana shareholders will own approximately 98.5% of the combined entity, which will be renamed Korsana and trade under the ", "url": "https://www.biocentury.com/article/659048/alzheimer-s-company-korsana-heads-to-nasdaq-via-merger-deals-report", "source_name": "BioCentury", "published_at": "2026-04-06T21:12:00", "published_display": "06 Apr 2026 21:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the proposed merger between Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. The firm is concerned that Cyclerion shareholders, who are expected to own only 1.5% of the combined company, may ", "url": "https://www.wfxg.com/online_features/press_releases/cycn-stock-alert-halper-sadeh-llc-is-investigating-whether-cyclerion-therapeutics-inc-is-obtaining-a/article_5bc11855-2a03-5104-9196-263dbcdd1f32.html", "source_name": "WFXG", "published_at": "2026-04-05T10:39:07", "published_display": "05 Apr 2026 10:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN PE Ratio & Valuation, Is CYCN Overvalued", "summary": "Cyclerion Therapeutics Inc. (CYCN) is currently considered undervalued based on its forward PS ratio of 2.31 compared to its five-year average. Its fair price is estimated to be between $7.83 and $11.65, making the current price of $6.15 USD approximately 21.42% undervalued. Desp", "url": "https://intellectia.ai/en/stock/CYCN/valuation", "source_name": "Intellectia AI", "published_at": "2026-04-05T07:10:42", "published_display": "05 Apr 2026 07:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)", "summary": "Monteverde & Associates PC, a class action law firm, has announced an investigation into Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) following its proposed merger with Korsana Biosciences, Inc. The firm is examining whether the deal, which would result in current Cyclerion shareh", "url": "https://www.sahmcapital.com/news/content/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cyclerion-therapeutics-inc-nasdaq-cycn-2026-04-02", "source_name": "Sahm", "published_at": "2026-04-03T09:41:03", "published_display": "03 Apr 2026 09:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monteverde & Associates Investigates Cyclerion Therapeutics Merger", "summary": "Monteverde & Associates PC, a national class action securities firm, has launched an investigation into the proposed merger between Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. The firm is examining whether the deal's terms, which would leave Cyclerio", "url": "https://nationaltoday.com/us/ny/new-york/news/2026/04/02/monteverde-associates-investigates-cyclerion-therapeutics-merger/", "source_name": "National Today", "published_at": "2026-04-02T19:40:02", "published_display": "02 Apr 2026 19:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQOUlnTnhxa0lkVkJadHhqZFNUbVNaQjZicGlVbjhkcDROenRGd0dYbkMtVm1DZXlKMmpTYk13RXZlaXQyMi1FN3NuenRhZVpVNkZaMjZvU1Qtc2dmQ18yUDVTSGZRc2VVVUJxSjVoVUUtc29IVDNSdkVKVGx3eDF3aEJxRGo4QlA0UC1YUUVJdERFR0trNkFYc0lUM3V0emYwZjFydEtFOTBORGVZNjFPOVBhYjJMcjFZdDZVY0RUYw?oc=5", "source_name": "International Business Times Australia", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Merger Sparks Investor Uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOTnBJaVZGMnNSTmhTN3dpbElCazY1RTZ0czAtTkxzaFIyTHlkU3pJeTM1a0k5bVd5cmg3cWZGYVN3MVVSN05LWG1uNkwzMXZVWS14OVNnRWIyREZhYU5pMVFpUVJfakpxT09MeE1RQS1fVWVURXU1MzZ1UXRDVkNyQWNMMUFmOHhmRnc?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion and Korsana Tie the Knot with a New Merger Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQMUJQelFGMU1RZ0k3UEczd2o0RTVnYzJWdWZMakNpclZyWWRBY1F5VGRzTjJzSE5reW5xSjdXcTlGSU1ab3BrUG05Y1dKZnJFN1FJVjAtN21sc1owVFk5UTVKaUpPdjYxVUZiZjR2dDRoLU8tMlRiTmc5WThCWkNMeDd6ZlA5QQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion to Merge With Korsana; $380 Million PIPE, CVRs and Lock-Ups Support Deal", "summary": "Cyclerion Therapeutics has announced a merger agreement with Korsana Biosciences, after which the combined entity will operate under the Korsana name. The deal is backed by a $380 million private placement, contingent value rights for Cyclerion shareholders, and lock-up agreement", "url": "https://www.tradingview.com/news/tradingview:070316a44d93f:0-cyclerion-to-merge-with-korsana-380-million-pipe-cvrs-and-lock-ups-support-deal/", "source_name": "TradingView \u2014 Track All Markets", "published_at": "2026-04-02T05:38:53", "published_display": "02 Apr 2026 05:38", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics surges as it agrees to merge with Korsana Biosciences in a deal backed by a large private financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPZHR6cFFTVGYtSjROd0IyQk5nU1d0Ymg2ZFpWMFFvYjNRenl5YUQwUU1QeDdGTS1idGZuXzkwTVktTndlVVppaUZ0dnUtSUN0LXlIa0tkVkhoSHN0SVZnQlJjNGw2Sm9zRFZrQVJoU3ZVUjFuenc5bnNlNFhjajhTaVBCSV9aUWlGZVM1U1pIV204SWN6aFJTeVMyd1ZEQzB3NHpIRFRQRW82QzY0NzBvLUlhXzZhSkg3ZHZCX3pGeEVFX3pqNlRUZ0p2dHRhUjVOYlU2d1RlUGVEc2tsUWkxaGFrNUFmLWEwMUNj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNdHpldnBQOGlIV3k2QVkzNThWR0gyWl9nMTE5X2dqQVRoUmNtRHlqMWlXSVhmakc0ZXlGd2tNcGVVMUpuN3BzOTRmajhtNkFiblZHN1JWMUdXUkZhS3VBaFZzcWZlNi1RaE5PVE1lVUFXTFZ1Mm5yc1FxYmtFS3BsbzFwSDBWb3Y0WlJ2WFNWOU8?oc=5", "source_name": "Investorideas.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Cyclerion Therapeutics Shoots up 322.9%", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQekd3ZFZmSll4WGt3TEp4MnpsUFJxTEl1OF9KNHdjekhpYkl2WkxwTlMzTW9KZlEtQVJJY2w4NlJhMEtzUXRyV3dCWFFvZDY5ZmlIR1RHRlg2eWdNRkU2b0hsMWhHQWJ5MllwMjZUMnpqcHdxTmdxMGQ2LUc3ZEtzOTNRV3paRDUwREp6OXo3eldDeFk0SFhKOUJjZkZWNnFNd0FGVQ?oc=5", "source_name": "Moomoo", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOQ29oUHNHaFNJTGxOLWF0UGJJU1BsQXRxZjdfRmlHSm1VelB3X1dkODVqbnZ1QmdwazJnakZXbVM4WlVQUzR1S05IQ3pxd3Z5SjJUaHVaVWViRjJCUjZlOFE0dUVCZkIyU0g1TDBjbWh6b09YQVVuR0pwZkVLc3lSel9LVnlYMXQzdml1REhYOXdLbUVSaERDMTNrWmREc0F4M1YxeEtncU1ERS1Kc2RISXRaMlVXVzNjdG9vZEtCTzM3OEFfSVMxMQ?oc=5", "source_name": "Business Wire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Stock Rallies As Research Venture Promises Bright Future", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOY2l5d2RrelJ2d1piYXVldlNLTmFQYjRGSXl1Qk03WWRUd1BTS3hpWkVONUdfVFNwckcwMFNmai16V2R3eGNtYkt5dDUtdU1hcnhJc0MyR0lRNmpWNjdZMWxBQk5mdzdfQUg2dkRaeDRiMW5GR21aUzdGaEIxaWJpeERwZm9mYkxoMkE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cyclerion Therapeutics Collaboration Sparks Curiosity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNd2gyQk51YTZ1cmk0WlVnWl9FMlZYQnk1NW1fS2hPUUtkeXF3V1VqOUFjMlpCN05UektTalliRHRoOE15WVpsYjBRMFFTZ3lubXhScHZDcDJfOFE1dHRXdXF1RGZwWHNnQ29Cb1pJZ3owTDNCMUZRSVJTRkhjdDJZWDlMUjlXMjQxU1E?oc=5", "source_name": "timothysykes.com", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics stock soars after strategic Medsteer collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOYXk5WTBOSl9mTS1wSXZoaTQxV0JxbVIxS3JFMlpCc3hUZkhmZlRsVEszbkhxLVN3VkgyWjBfb1hhOFdtU2E3N0h0ZWxXaGkxMnN1WTNERHNyalE1dUcxR0pVaXdSRFJaLWVuX3Y3d2JndzFaT1JPdXE0eEh0VUtydGFjbDBsVUVjb0FtbmJkamZxb2hTNktxZExoY3BkWng0U1ZDMWpFSk5iMzlzbVZwenBCaTVfSkExMVRjOEtuRXhBMEZoLW5UODUyZXpVdFdH?oc=5", "source_name": "Investing.com", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1qdk9nQ0ctN09NczBocGZLVUg4RVRGbDBCRkhvVHB3bnpOM0tvbEo3c3lPdlUybDdJRmFabWlyRUF2Q0lsMXMzZ0FQQkNXOEQzLWRV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:08:53+00:00", "published_display": "25 Apr 2025 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxPMS1JbGF3RzBseXN6Z3RfcDlsRWpMQ29OMmhWUmQwcHRqUEFicjJMdzJIUXIxNThXQU11N0FrckJnVjNvQTB4NXJQTHRkdklocU5EdVpYM2VvNFBzblZteGx6My1wUXN4ckl5dnhyZjZXc0VMeklpRVBtdGloVHF6QU5NX2RzcTNVSE83bTFUUm82MHM0S1VEWTd2UTFFV0ZxQ1AweWlfRmhjdUJMbGJjMHFhY0RFR2lpb0dtQVVqQ2J5UGpnSmhZVUxicXhKN3dlQ1k3cjQxU2xwc0VOVEo4Q0xfT3RIaGs2a1M0dVdzazlacHdCRjBSSEh0TTRWa2tsVlE?oc=5", "source_name": "Business Upturn", "published_at": "2024-12-04T08:00:00+00:00", "published_display": "04 Dec 2024 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN: Cyclerion Therapeutics - Full Company Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9YVThsbTRUTFBCMHNjNWlRZ1NCdHpSXzBPWjg4eElPYVN2ZjEwdnYxX3I3TUs2UWhESXdvSjU5ajFVYXBXSTVqY05TTHA2ZEcxUEI3bU5PM0x4NW9NaUhNU0d1MFFidWxx?oc=5", "source_name": "Zacks Investment Research", "published_at": "2019-04-10T13:43:41+00:00", "published_display": "10 Apr 2019 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cyclerion Therapeutics (CYCN) Edges Lower, Testing Key Support Amid Low Volume - New Highs New Lows", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQQXhIemZkQWtZdmF1bDBZb2podWNjWk4ySjBieFBmcGF5LWU0Y0h6NXp1emRVTDc2Tkw4aHRGazU5QzluMGhvd2NHMFRDaHNMU0I1VVE1R1Fvc0pLc0JCUVBMdWlWeVd0bm1nYUNDLVI4MjhUV3hrdmRfeDgyZUpLRjBaZDJsa0hwQS1UVTRNc09tWTNRbTRlbEVxWnlfSkZKcE1BNV9fSnJSWEl1ZXJycTU5TlRMajhJcHdr?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-15T00:30:26+00:00", "published_display": "15 Jul 2026 00:30", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal", "summary": "Cyclerion Therapeutics plans a reverse merger with privately held Korsana Biosciences, combined with a concurrent $380 million private placement. The new entity will focus on neurodegenerative diseases, particularly Alzheimer's, utilizing Korsana's THETA blood-brain barrier platf", "url": "https://www.stocktitan.net/sec-filings/CYCN/425-cyclerion-therapeutics-inc-business-combination-communication-65f7e735e4c8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:10:50", "published_display": "10 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDGAR Filing Documents for 0001193125-26-301054", "summary": "This SEC filing details a Form 425 submission by Cyclerion Therapeutics, Inc., accessible via the EDGAR system. The filing, with accession number 0001193125-26-301054, was made on July 10, 2026, and includes numerous documents and graphic files related to prospectuses and communi", "url": "https://www.sec.gov/Archives/edgar/data/1755237/000119312526301054/0001193125-26-301054-index.htm", "source_name": "SEC.gov", "published_at": "2026-07-10T15:39:35", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQUmRTd1BWdlNOSVVTRlRIOGZXUXRLS25HdXdiRFB1aHdkV2xBTHVkbjhZem52TmNBdXd1RmVKUGQwWTdrUEdFNGFaOEFuMWN4enREaU5HRFI0bVJyTko1bGVjSGtoQ0J6RUdIcDRKcS1DNUZ4dHZ6QXNrR2dNWkF4b0hKRDBiaDdBX2VRV2pSYi1NMWRyQlR2RFc0a0xHbWJjRnBSTHM4eU1fREhVeTZ1MkZzRkk3UFByUUJlSXZOZHNIWUkxX1BOS2Fhdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T10:05:52+00:00", "published_display": "10 Jul 2026 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. \u2013 NASDAQ:CYCN", "summary": "The article focuses on the enterprise value to forward revenue metric for Cyclerion Therapeutics, Inc. (NASDAQ: CYCN). It presents this financial data point for the company. The content appears to be a financial data snippet from TradingView, part of a larger analysis tool.", "url": "https://www.tradingview.com/symbols/NASDAQ-CYCN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:35", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cyclerion Therapeutics, Inc. \u2013 NASDAQ:CYCN", "summary": "This article provides a brief snapshot of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) focusing on its forward price to sales metric. It highlights the company's financial data availability on TradingView, indicating no current trades and a closed market status. The content is prim", "url": "https://www.tradingview.com/symbols/NASDAQ-CYCN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:43", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN)", "summary": "This article provides an overview of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) including its stock performance, market capitalization, and financial estimates. It highlights key financial data such as net income and EBITDA, and answers frequently asked questions regarding the c", "url": "https://www.tradingview.com/symbols/NASDAQ-CYCN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:41:29", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key Resistance - Triple MA Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOUVCRTRobng5R09DcDRfU0ttMlViQlNuZVItanRHajRndDg2RmI2cHhIbU9WRXphaDdfY1RCbDBzMU4zRThLNS1fT0tUb3J6dUpPSkhLMi1oWTB4WEs4SURvUTlPNTZYVE5OVWEzY3MtTVM2Yk10MnBCUE00MUV2TU8wWjJEUUtYT0NWOWhTZnhrcVRKb1E3UnJSN1lQMTBnQmUzbG1feW96OWVSVHZ6d1luOUdUVEtJcUpJ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey.com discusses Cyclerion Therapeutics Inc (CYCN) and its revenue breakdown. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides basic stock inf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cycn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:16", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis", "summary": "Cyclerion Therapeutics Inc (CYCN) currently holds a valuation score of 8.51, positioning it 126th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -2.44, indicating a significant deviation from its recent high and low P/E va", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cycn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T04:40:48", "published_display": "16 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Company Profile & Introduction", "summary": "This document provides a company profile and introduction for Cyclerion Therapeutics. Further details about the company's operations, financial health, or strategic initiatives would be found within the full content of such a profile.", "url": "https://www.moomoo.com/stock/CYCN-US/company?chain_id=Name1K9-3FXPhg.1ksr1qg&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A62,%22f%22%3A%22mm%2Fcommunity%2Fnnq%22%7D", "source_name": "Moomoo", "published_at": "2026-05-28T00:10:04", "published_display": "28 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] Cyclerion Therapeutics, Inc. Quarterly Earnings Report", "summary": "Cyclerion Therapeutics reported a wider net loss of $3.2 million in Q1 2026 with no revenue, while operating expenses rose. The company faces a significant cash crunch, with funds expected to last only into Q3 2026, prompting substantial doubt about its ability to continue as a g", "url": "https://www.stocktitan.net/sec-filings/CYCN/10-q-cyclerion-therapeutics-inc-quarterly-earnings-report-3de9078065ab.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:39:45", "published_display": "12 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G", "summary": "FMR LLC has reported a 15.0% beneficial ownership stake in Cyclerion Therapeutics (NASDAQ: CYCN), as detailed in a Schedule 13G filing. The investment firm beneficially owns 649,547 shares of common stock as of April 30, 2026, with sole dispositive power. This includes holdings b", "url": "https://www.stocktitan.net/sec-filings/CYCN/schedule-13g-cyclerion-therapeutics-inc-passive-investment-disclosure-747ebc5daaa8.html", "source_name": "Stock Titan", "published_at": "2026-05-07T14:39:35", "published_display": "07 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating Organon & Co. (OGN), TruBridge, Inc. (TBRG), and Cyclerion Therapeutics, Inc. (CYCN) for potential violations of federal securities laws and breaches of fiduciary duties related to their recent or proposed transactio", "url": "https://www.sahmcapital.com/news/content/are-ogn-tbrg-cycn-obtaining-fair-deals-for-their-shareholders-2026-05-04", "source_name": "Sahm", "published_at": "2026-05-04T22:39:30", "published_display": "04 May 2026 22:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading", "summary": "This page provides an overview of insider trading activity for Cyclerion Therapeutics, Inc. (CYCN), alongside other financial data. It indicates no recent insider trading by directors and management, and no congressional trading data for the ticker. The article also lists signifi", "url": "https://www.quiverquant.com/stock/CYCN/insiders/", "source_name": "Quiver Quantitative", "published_at": "2026-05-03T06:11:00", "published_display": "03 May 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details", "summary": "Cyclerion Therapeutics filed an amended annual report (10-K/A) to provide detailed disclosures on its board structure, executive compensation, and share ownership, which were previously omitted. The report highlights an independent chairman, three key board committees, and polici", "url": "https://www.stocktitan.net/sec-filings/CYCN/10-k-a-cyclerion-therapeutics-inc-amends-annual-report-d02ab0a422dc.html", "source_name": "Stock Titan", "published_at": "2026-04-30T12:39:14", "published_display": "30 Apr 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN SEC Filings - Cyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for investors and traders to access Cyclerion Therapeutics (CYCN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details how these documents offer insights into the company's", "url": "https://www.stocktitan.net/sec-filings/CYCN/page-2.html", "source_name": "Stock Titan", "published_at": "2026-04-29T08:40:21", "published_display": "29 Apr 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy", "summary": "Cyclerion Therapeutics and Korsana Biosciences have merged to form a new entity, Korsana Biosciences (KRSA), focused on developing neurodegenerative disease treatments. The combined company will prioritize KRSA-028, a new antibody targeting amyloid beta for Alzheimer's disease, u", "url": "https://www.harianbasis.co/en/cyclerion-korsana-merger-alzheimer-research", "source_name": "HarianBasis.co", "published_at": "2026-04-22T12:09:51", "published_display": "22 Apr 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer\u2019s Pipeline", "summary": "Cyclerion Therapeutics (NASDAQ:CYCN) has merged with Korsana Biosciences to form a new entity, also named Korsana Biosciences, trading under the ticker 'KRSA'. The merger aims to advance Korsana's neurodegenerative pipeline, specifically targeting Alzheimer's disease with KRSA-02", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cyclerion-therapeutics-cycn-merges-korsana-141501551.html", "source_name": "Market source", "published_at": "2026-04-20T16:15:00", "published_display": "20 Apr 2026 16:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korsana deal gives investors control; Cyclerion to become Korsana Biosciences (CYCN \u2192 KRSA)", "summary": "Cyclerion Therapeutics is merging with Korsana Biosciences, a privately held biotechnology company focused on neurodegenerative diseases. The merger will result in current Korsana shareholders owning approximately 98.5% of the combined company, which will be renamed Korsana Biosc", "url": "https://www.stocktitan.net/sec-filings/CYCN/s-4-cyclerion-therapeutics-inc-business-combination-registration-47f61d19e9a1.html", "source_name": "Stock Titan", "published_at": "2026-04-17T16:40:20", "published_display": "17 Apr 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing", "summary": "Cyclerion Therapeutics (CYCN) went up 350% in after-hours trading following the announcement of its merger with Korsana, a private biotechnology firm. The combined entity, specializing in therapies for inflammatory, fibrotic, and renal diseases, will be capitalized with $380 mill", "url": "https://www.msn.com/en-us/health/other/cyclerion-therapeutics-stock-soars-350-on-korsana-merger-380-million-financing/ar-AA1ZVt5m", "source_name": "MSN", "published_at": "2026-04-14T15:09:48", "published_display": "14 Apr 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time", "summary": "Replimune is implementing job cuts after the FDA rejected its drug candidate, RP1, for a second time. This development is part of a broader \"Finance Watch\" update which also covers Cyclerion, Kezar, and IO Biotech exploring strategic alternatives. The recurring FDA rejection for ", "url": "https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-replimune-cutting-jobs-as-fda-rejects-rp1-a-second-time-R7NN6KDVMVB65EL2YQQVSNVLJA/", "source_name": "Citeline News & Insights", "published_at": "2026-04-10T22:39:00", "published_display": "10 Apr 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating UniFirst (UNF), National Storage Affiliates Trust (NSA), Cyclerion Therapeutics (CYCN), and Urgent.ly (ULYX) for potential violations of federal securities laws and breaches of fiduciary duties related to their propo", "url": "https://www.prnewswire.com/news-releases/are-unf-nsa-cycn-ulyx-obtaining-fair-deals-for-their-shareholders-302738661.html", "source_name": "PR Newswire", "published_at": "2026-04-09T19:09:15", "published_display": "09 Apr 2026 19:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s company Korsana heads to NASDAQ via merger: Deals Report", "summary": "Korsana Biosciences Inc., an Alzheimer's focused company, will go public on NASDAQ through a reverse merger with Cyclerion Therapeutics Inc. (NASDAQ:CYCN). Korsana shareholders will own approximately 98.5% of the combined entity, which will be renamed Korsana and trade under the ", "url": "https://www.biocentury.com/article/659048/alzheimer-s-company-korsana-heads-to-nasdaq-via-merger-deals-report", "source_name": "BioCentury", "published_at": "2026-04-06T21:12:00", "published_display": "06 Apr 2026 21:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the proposed merger between Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. The firm is concerned that Cyclerion shareholders, who are expected to own only 1.5% of the combined company, may ", "url": "https://www.wfxg.com/online_features/press_releases/cycn-stock-alert-halper-sadeh-llc-is-investigating-whether-cyclerion-therapeutics-inc-is-obtaining-a/article_5bc11855-2a03-5104-9196-263dbcdd1f32.html", "source_name": "WFXG", "published_at": "2026-04-05T10:39:07", "published_display": "05 Apr 2026 10:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN PE Ratio & Valuation, Is CYCN Overvalued", "summary": "Cyclerion Therapeutics Inc. (CYCN) is currently considered undervalued based on its forward PS ratio of 2.31 compared to its five-year average. Its fair price is estimated to be between $7.83 and $11.65, making the current price of $6.15 USD approximately 21.42% undervalued. Desp", "url": "https://intellectia.ai/en/stock/CYCN/valuation", "source_name": "Intellectia AI", "published_at": "2026-04-05T07:10:42", "published_display": "05 Apr 2026 07:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)", "summary": "Monteverde & Associates PC, a class action law firm, has announced an investigation into Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) following its proposed merger with Korsana Biosciences, Inc. The firm is examining whether the deal, which would result in current Cyclerion shareh", "url": "https://www.sahmcapital.com/news/content/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-cyclerion-therapeutics-inc-nasdaq-cycn-2026-04-02", "source_name": "Sahm", "published_at": "2026-04-03T09:41:03", "published_display": "03 Apr 2026 09:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monteverde & Associates Investigates Cyclerion Therapeutics Merger", "summary": "Monteverde & Associates PC, a national class action securities firm, has launched an investigation into the proposed merger between Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. The firm is examining whether the deal's terms, which would leave Cyclerio", "url": "https://nationaltoday.com/us/ny/new-york/news/2026/04/02/monteverde-associates-investigates-cyclerion-therapeutics-merger/", "source_name": "National Today", "published_at": "2026-04-02T19:40:02", "published_display": "02 Apr 2026 19:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQOUlnTnhxa0lkVkJadHhqZFNUbVNaQjZicGlVbjhkcDROenRGd0dYbkMtVm1DZXlKMmpTYk13RXZlaXQyMi1FN3NuenRhZVpVNkZaMjZvU1Qtc2dmQ18yUDVTSGZRc2VVVUJxSjVoVUUtc29IVDNSdkVKVGx3eDF3aEJxRGo4QlA0UC1YUUVJdERFR0trNkFYc0lUM3V0emYwZjFydEtFOTBORGVZNjFPOVBhYjJMcjFZdDZVY0RUYw?oc=5", "source_name": "International Business Times Australia", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Merger Sparks Investor Uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOTnBJaVZGMnNSTmhTN3dpbElCazY1RTZ0czAtTkxzaFIyTHlkU3pJeTM1a0k5bVd5cmg3cWZGYVN3MVVSN05LWG1uNkwzMXZVWS14OVNnRWIyREZhYU5pMVFpUVJfakpxT09MeE1RQS1fVWVURXU1MzZ1UXRDVkNyQWNMMUFmOHhmRnc?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion and Korsana Tie the Knot with a New Merger Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQMUJQelFGMU1RZ0k3UEczd2o0RTVnYzJWdWZMakNpclZyWWRBY1F5VGRzTjJzSE5reW5xSjdXcTlGSU1ab3BrUG05Y1dKZnJFN1FJVjAtN21sc1owVFk5UTVKaUpPdjYxVUZiZjR2dDRoLU8tMlRiTmc5WThCWkNMeDd6ZlA5QQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion to Merge With Korsana; $380 Million PIPE, CVRs and Lock-Ups Support Deal", "summary": "Cyclerion Therapeutics has announced a merger agreement with Korsana Biosciences, after which the combined entity will operate under the Korsana name. The deal is backed by a $380 million private placement, contingent value rights for Cyclerion shareholders, and lock-up agreement", "url": "https://www.tradingview.com/news/tradingview:070316a44d93f:0-cyclerion-to-merge-with-korsana-380-million-pipe-cvrs-and-lock-ups-support-deal/", "source_name": "TradingView \u2014 Track All Markets", "published_at": "2026-04-02T05:38:53", "published_display": "02 Apr 2026 05:38", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics surges as it agrees to merge with Korsana Biosciences in a deal backed by a large private financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPZHR6cFFTVGYtSjROd0IyQk5nU1d0Ymg2ZFpWMFFvYjNRenl5YUQwUU1QeDdGTS1idGZuXzkwTVktTndlVVppaUZ0dnUtSUN0LXlIa0tkVkhoSHN0SVZnQlJjNGw2Sm9zRFZrQVJoU3ZVUjFuenc5bnNlNFhjajhTaVBCSV9aUWlGZVM1U1pIV204SWN6aFJTeVMyd1ZEQzB3NHpIRFRQRW82QzY0NzBvLUlhXzZhSkg3ZHZCX3pGeEVFX3pqNlRUZ0p2dHRhUjVOYlU2d1RlUGVEc2tsUWkxaGFrNUFmLWEwMUNj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNdHpldnBQOGlIV3k2QVkzNThWR0gyWl9nMTE5X2dqQVRoUmNtRHlqMWlXSVhmakc0ZXlGd2tNcGVVMUpuN3BzOTRmajhtNkFiblZHN1JWMUdXUkZhS3VBaFZzcWZlNi1RaE5PVE1lVUFXTFZ1Mm5yc1FxYmtFS3BsbzFwSDBWb3Y0WlJ2WFNWOU8?oc=5", "source_name": "Investorideas.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Cyclerion Therapeutics Shoots up 322.9%", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQekd3ZFZmSll4WGt3TEp4MnpsUFJxTEl1OF9KNHdjekhpYkl2WkxwTlMzTW9KZlEtQVJJY2w4NlJhMEtzUXRyV3dCWFFvZDY5ZmlIR1RHRlg2eWdNRkU2b0hsMWhHQWJ5MllwMjZUMnpqcHdxTmdxMGQ2LUc3ZEtzOTNRV3paRDUwREp6OXo3eldDeFk0SFhKOUJjZkZWNnFNd0FGVQ?oc=5", "source_name": "Moomoo", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOQ29oUHNHaFNJTGxOLWF0UGJJU1BsQXRxZjdfRmlHSm1VelB3X1dkODVqbnZ1QmdwazJnakZXbVM4WlVQUzR1S05IQ3pxd3Z5SjJUaHVaVWViRjJCUjZlOFE0dUVCZkIyU0g1TDBjbWh6b09YQVVuR0pwZkVLc3lSel9LVnlYMXQzdml1REhYOXdLbUVSaERDMTNrWmREc0F4M1YxeEtncU1ERS1Kc2RISXRaMlVXVzNjdG9vZEtCTzM3OEFfSVMxMQ?oc=5", "source_name": "Business Wire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Stock Rallies As Research Venture Promises Bright Future", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOY2l5d2RrelJ2d1piYXVldlNLTmFQYjRGSXl1Qk03WWRUd1BTS3hpWkVONUdfVFNwckcwMFNmai16V2R3eGNtYkt5dDUtdU1hcnhJc0MyR0lRNmpWNjdZMWxBQk5mdzdfQUg2dkRaeDRiMW5GR21aUzdGaEIxaWJpeERwZm9mYkxoMkE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics Collaboration Sparks Curiosity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNd2gyQk51YTZ1cmk0WlVnWl9FMlZYQnk1NW1fS2hPUUtkeXF3V1VqOUFjMlpCN05UektTalliRHRoOE15WVpsYjBRMFFTZ3lubXhScHZDcDJfOFE1dHRXdXF1RGZwWHNnQ29Cb1pJZ3owTDNCMUZRSVJTRkhjdDJZWDlMUjlXMjQxU1E?oc=5", "source_name": "timothysykes.com", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics stock soars after strategic Medsteer collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOYXk5WTBOSl9mTS1wSXZoaTQxV0JxbVIxS3JFMlpCc3hUZkhmZlRsVEszbkhxLVN3VkgyWjBfb1hhOFdtU2E3N0h0ZWxXaGkxMnN1WTNERHNyalE1dUcxR0pVaXdSRFJaLWVuX3Y3d2JndzFaT1JPdXE0eEh0VUtydGFjbDBsVUVjb0FtbmJkamZxb2hTNktxZExoY3BkWng0U1ZDMWpFSk5iMzlzbVZwenBCaTVfSkExMVRjOEtuRXhBMEZoLW5UODUyZXpVdFdH?oc=5", "source_name": "Investing.com", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1qdk9nQ0ctN09NczBocGZLVUg4RVRGbDBCRkhvVHB3bnpOM0tvbEo3c3lPdlUybDdJRmFabWlyRUF2Q0lsMXMzZ0FQQkNXOEQzLWRV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:08:53+00:00", "published_display": "25 Apr 2025 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxPMS1JbGF3RzBseXN6Z3RfcDlsRWpMQ29OMmhWUmQwcHRqUEFicjJMdzJIUXIxNThXQU11N0FrckJnVjNvQTB4NXJQTHRkdklocU5EdVpYM2VvNFBzblZteGx6My1wUXN4ckl5dnhyZjZXc0VMeklpRVBtdGloVHF6QU5NX2RzcTNVSE83bTFUUm82MHM0S1VEWTd2UTFFV0ZxQ1AweWlfRmhjdUJMbGJjMHFhY0RFR2lpb0dtQVVqQ2J5UGpnSmhZVUxicXhKN3dlQ1k3cjQxU2xwc0VOVEo4Q0xfT3RIaGs2a1M0dVdzazlacHdCRjBSSEh0TTRWa2tsVlE?oc=5", "source_name": "Business Upturn", "published_at": "2024-12-04T08:00:00+00:00", "published_display": "04 Dec 2024 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYCN: Cyclerion Therapeutics - Full Company Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9YVThsbTRUTFBCMHNjNWlRZ1NCdHpSXzBPWjg4eElPYVN2ZjEwdnYxX3I3TUs2UWhESXdvSjU5ajFVYXBXSTVqY05TTHA2ZEcxUEI3bU5PM0x4NW9NaUhNU0d1MFFidWxx?oc=5", "source_name": "Zacks Investment Research", "published_at": "2019-04-10T13:43:41+00:00", "published_display": "10 Apr 2019 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 50, "sentiment_summary": {"positive": 10, "negative": 8, "neutral": 32, "score": 51, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "deals", "label": "Deals and strategy", "weight": 8.25, "count": 15}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}], "positive_events": 10, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 3.83, "latest_week": "2026-07-10", "one_week_move": 11.8, "four_week_move": 18.0, "twelve_week_move": 27.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.015758, "market_dynamics_buy_signal": false, "relative_strength": 43.313108, "fair_value_gap": 37.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 38.1232, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+11.8% over one week, +18.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "timothysykes.com", "count": 3}, {"label": "TradingKey", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Deals and strategy", "count": 15}, {"label": "Earnings", "count": 11}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+11.8% over one week, +18.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Cyclerion Therapeutics (CYCN) Edges Lower, Testing Key Support Amid Low Volume - New Highs New Lows"}], "updated_at": "2026-07-16T04:34:59.450927+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}